Financhill
Back

Kura Oncology Quote, Financials, Valuation and Earnings

Kura Oncology Price Quote

$19.77
+0.15 (+0.76%)
(Updated: May 1, 2024 at 12:50 PM ET)

Kura Oncology Key Stats

Buy
67
Kura Oncology (KURA) is a Buy

Day range:
$19.60 - $20.35
52-week range:
$7.41 - $24.17
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
3.76%

Volume:
418.4K
Avg. volume:
822.2K
1-year change:
101.44%
Market cap:
$1.5B
Revenue:
$0
EPS:
$-2.08

How Much Does Kura Oncology Make?

Data Unavailable

Is Kura Oncology Growing As A Company?

Data Unavailable

Kura Oncology Stock Price Performance

  • Did Kura Oncology Stock Go Up Last Month?
    Kura Oncology share price went down by -8.02% last month
  • Did KURA's Share Price Rise Over The Last Year?
    KURA share price rose by 101.44% over the past 1 year

What Is Kura Oncology 52-Week High & Low?

Kura Oncology Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Kura Oncology?

  • How Much Debt Does Kura Oncology Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Kura Oncology Have?
    Cash and short term investments quarterly total is $424M
  • What Is Kura Oncology’s Book Value Per Share?
    Book value per share is 5.34

Is Kura Oncology Cash Flow Positive?

  • What Is KURA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$124.8M
  • What Is Kura Oncology’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $94.8M
  • What Is Kura Oncology’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $15.6M

Kura Oncology Return On Invested Capital

Data Unavailable

Kura Oncology Earnings Date & Stock Price

Kura Oncology Competitors

  • Who Are Kura Oncology's Competitors?
    Below is a list of companies who compete with Kura Oncology or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Protalix BioTherapeutics Inc (PLX)
    • Tivic Health Systems Inc (TIVC)

Kura Oncology Dividend Yield

Data Unavailable

Kura Oncology Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.05%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 10
Hold Recommendations: 1
Sell Recommendations: 0
Price Target: 30.25
Upside from Last Price: 54.18%

Major Shareholders

  • How many KURA shares are owned by institutional investors?
    115.6M KURA shares are owned by institutional investors
  • How many KURA shares are owned by insiders?
    575.5K KURA shares are owned by insiders